Literature DB >> 8112655

Uterine malignant mixed müllerian tumor in a patient on long-term tamoxifen therapy for breast cancer.

M R Clarke1.   

Abstract

A case of malignant mixed müllerian tumor of the uterus, heterologous type, in an 83-year-old woman on tamoxifen (TAM) therapy for 9 years for breast cancer is presented. Benign endometrial polyps were diagnosed on endometrial curettings for postmenopausal bleeding after the patient had been on TAM for 5 years. Recurrent postmenopausal bleeding developed 4 years later. Endometrial curettings and hysterectomy revealed a 10-cm polypoid malignant mixed müllerian tumor (MMMT) and endometrial polyps. There was no invasion of the myometrium or endocervix and no evidence of metastatic tumor in 13 pelvic lymph nodes, peritoneal washings, or omentum. TAM has been associated with the development of endometrial polyps, hyperplasia, and adenocarcinoma possibly mediated through its agonistic estrogenic properties. Only one other case of MMMT arising in patients on TAM therapy has been previously reported, but may also be a consequence of the estrogenic effects of TAM therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8112655     DOI: 10.1006/gyno.1993.1314

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

1.  MALIGNANT MIXED MULLERIAN TUMOURS.

Authors:  Prabal Deb; D Swarup; A Dwiwedi
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 2.  Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Müllerian tumor and sarcoma-A report of 8 cases and review of the literature.

Authors:  Ana Luisa Cardoso Vasconcelos; Beatriz Nunes; Catarina Duarte; Vera Mendonça; Joana Ribeiro; Marília Jorge; Isabel Monteiro Grillo
Journal:  Rep Pract Oncol Radiother       Date:  2013-08-12

Review 3.  Tamoxifen and secondary tumours. An update.

Authors:  N Wilking; E Isaksson; E von Schoultz
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

Review 4.  Gynaecologic effects of tamoxifen.

Authors:  D Y Kuo; C D Runowicz
Journal:  Med Oncol       Date:  1995-06       Impact factor: 3.064

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.